Reimbursement for HPV Vaccine Cost in the Private Sector: A Comparison Across Specialties.
Where this comes from
- Record sourced from PubMed, PMID 37487718.
- Also identified by DOI 10.1370/afm.2990 and PMC identifier 10365861.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The human papillomavirus (HPV) vaccine is the most expensive of all routinely recommended pediatric vaccines. Adequate cost reimbursement by 3rd-party payers is a critical enabling factor for clinicians to continue offering vaccines. This study found that net returns from HPV vaccine cost reimbursements are lowest for family physicians ($0.34/dose) and highest for pediatricians ($5.08/dose). Furthermore, a $1 increment in return was associated with an increase in HPV vaccine doses administered (highest for family physicians; 0.08% per dollar). Reimbursement for HPV vaccine costs by private payers is adequate; however, return margins are small for non-pediatric specialties.
Medical subject headings
- Papillomavirus Vaccines
- Medicine